USFDA grants Sun Pharma tentative approval for generic Stalevo ANDA

Download PDF Copy

Oct 1 2010

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Orion's Stalevo^® tablets.

These generic Carbidopa, Levodopa and Entacapone tablets contain Carbidopa, Levodopa and Entacapone 25/100/200 mg, and 37.5/150/200 mg.

Generic Carbidopa, Levodopa and Entacapone tablets are indicated in the treatment of Parkinson's disease.

These strengths of Stalevo^® have annual sales of approximately $ 95 million in the US.

Source:

Sun Pharmaceutical Industries Ltd.

Posted in: Medical Condition News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

University of Vienna team develops method to measure molecular charges

COPD care pathways improve hospital outcomes and standardize treatment

Mushrooms deliver nutrition medicine and sustainability solutions in one package

Hypothalamic neurons help maintain blood sugar during daily activities

Gene editing restores hearing and balance in adult mice with DFNA41 deafness

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

New treatment approach developed to prevent lupus nephritis

International commission calls for action against hepatocellular carcinoma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.